Skip to main content
. Author manuscript; available in PMC: 2015 Oct 17.
Published in final edited form as: Am J Nephrol. 2014 Oct 17;40(4):300–307. doi: 10.1159/000367901

Table 2.

Number of events, follow-up time, incidence rates, and hazard ratios for death and recurrent gastrointestinal bleeding (GIB) in patients receiving heparin following GIB.

Outcome Exposure group N Number of events Follow-up time* (years) Incidence rate (per 100 person-years) Model Hazard ratio (95% CI)

Mean ± SD Median
All-cause mortality Did not receive heparin post-GIB 184 28 0.25±0.36 0.05 61.7

Received heparin post-GIB 1158 392 0.56±0.39 0.56 60.5 Unadjusted 1.01 (0.69–1.48)
Model 1 0.94 (0.64–1.40)
Model 2 0.91 (0.61–1.37)

Recurrent GIB Did not receive heparin post-GIB 184 9 0.23±0.35 0.04 21.4

Received heparin post-GIB 1158 81 0.54±0.40 0.49 13.0 Unadjusted 0.78 (0.39–1.57)
Model 1 0.66 (0.33–1.34)

SD=standard deviation CI=confidence interval

Model 1: adjusted for all variables that were significantly different between the groups in univariate analysis at the p<0.20 level (age, race, cancer, deep vein thrombosis, pulmonary embolism, transfusions received during hospitalization, days from hospital admission for GIB to resumption of outpatient HD, Kt/V, reuse of dialysis filter.)

Model 2: Model 1 + all demographics (age, sex, race, ethnicity, years on dialysis), all comorbidities (arrhythmia, cancer, coronary artery disease, deep vein thrombosis, diabetes mellitus, previous gastrointestinal bleeding, heart failure, hemorrhagic stroke, ischemic stroke, liver disease, peripheral vascular disease, pulmonary disease, pulmonary embolism), hemoglobin concentration, platelet count, and access type.